Xencor, Inc. (NASDAQ:XNCR) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.10, Morningstar.com reports. The firm had revenue of $13.34 million for the quarter, compared to the consensus estimate of $8.15 million. Xencor had a net margin of 18.19% and a return on equity of 5.98%.

Shares of Xencor (XNCR) traded up 5.00% during mid-day trading on Tuesday, reaching $23.33. 47,171 shares of the company’s stock were exchanged. The stock has a market capitalization of $1.09 billion, a PE ratio of 66.09 and a beta of 2.14. Xencor has a 1-year low of $18.45 and a 1-year high of $29.38. The company’s 50 day moving average is $22.34 and its 200 day moving average is $23.09.

Several analysts have recently commented on XNCR shares. Zacks Investment Research downgraded shares of Xencor from a “buy” rating to a “hold” rating in a research report on Saturday, April 29th. Wedbush restated an “outperform” rating and set a $29.00 price objective on shares of Xencor in a research report on Wednesday, May 10th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $28.67.

In related news, major shareholder John S. Stafford III acquired 1,500 shares of Xencor stock in a transaction on Friday, June 16th. The stock was bought at an average cost of $19.67 per share, for a total transaction of $29,505.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder John S. Stafford III acquired 6,000 shares of Xencor stock in a transaction on Wednesday, June 28th. The shares were bought at an average price of $19.94 per share, with a total value of $119,640.00. The disclosure for this purchase can be found here. Insiders have sold 34,766 shares of company stock valued at $739,408 over the last 90 days. 4.14% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of XNCR. Redmile Group LLC boosted its position in Xencor by 59.9% in the first quarter. Redmile Group LLC now owns 1,592,526 shares of the biopharmaceutical company’s stock worth $38,093,000 after buying an additional 596,426 shares in the last quarter. Norges Bank bought a new position in Xencor during the fourth quarter worth $15,601,000. State Street Corp boosted its position in Xencor by 17.5% in the first quarter. State Street Corp now owns 992,981 shares of the biopharmaceutical company’s stock worth $23,751,000 after buying an additional 148,136 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Xencor by 254.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 182,256 shares of the biopharmaceutical company’s stock worth $4,797,000 after buying an additional 130,778 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its position in Xencor by 54.5% in the first quarter. Acadian Asset Management LLC now owns 322,768 shares of the biopharmaceutical company’s stock worth $7,722,000 after buying an additional 113,862 shares in the last quarter. Institutional investors own 74.12% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/08/xencor-inc-xncr-releases-quarterly-earnings-results-beats-expectations-by-0-10-eps.html.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Earnings History for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.